JPMorgan Starts Ardent Health Partners Inc (ARDT) at Neutral

JPMorgan analyst Lisa Gill initiates coverage on Ardent Health Partners Inc (NYSE: ARDT) with a Neutral rating and a price target of $18.00.

The analyst comments: "We are initiating on Ardent Health (ARDT) with a Neutral rating and YE25 $18 price target, based on a 4.5x target multiple on 2026E EBITDA (~4.6x EBITDA-NCI). We believe ARDT's unique JV structure enables the company to focus on a different market segment (academic medical centers and not-for-profit systems) than its publicly traded peers. We are also positive on the company's exposure to markets with attractive population growth and income trends (key structural drivers for hospitals), top 3 share in all eight of its geographies, and potential for in-market expansions as well as new market entrances. With that said, our Neutral rating is based on our view that ARDT is more of a "show-me" story and that better near-term opportunities reside within our coverage universe."

For an analyst ratings summary and ratings history on Ardent Health Partners Inc click here. For more ratings news on Ardent Health Partners Inc click here.

Shares of Ardent Health Partners Inc closed at $15.64 yesterday.

You May Also Be Interested In

• Trane Technologies (TT) PT Raised to $555 at Bernstein SocGen Group
• Hershey (HSY) PT Lowered to $200 at Piper Sandler
• Meta launches first paid AI developer model with new API - Bloomberg